FDA clears Accuray's radiosurgery platform

The FDA has granted Accuray 510(k) clearance to market Lung Optimized Treatment, a component of the CyberKnife VSI system.

The Lung Optimized Treatment allows treatment of lung tumors without the need to implant fiducial markers, according to Sunnyvale, Calif.-based Accuray. Simulation and comparison workflows, combined with tracking modes, allow the clinician to select from multiple, non-invasive treatment options.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.